Bristol Myers Squibb (NYSE:BMY) Shares Unloaded Rep. Mike Kelly

Posted by Brenda Bartman on Jun 23rd, 2026

Representative Mike Kelly (Republican-Pennsylvania) recently sold shares of Bristol Myers Squibb Company (NYSE:BMY). In a filing disclosed on June 11th, the Representative disclosed that they had sold between $15,001 and $50,000 in Bristol Myers Squibb stock on May 7th. The trade occurred in the Representative’s “VICTORIA KELLY TRUST ICA” account.

Representative Mike Kelly also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Comcast (NASDAQ:CMCSA) on 5/7/2026.

Bristol Myers Squibb Price Performance

NYSE BMY traded up $0.91 during trading on Tuesday, hitting $55.61. 10,635,294 shares of the company’s stock were exchanged, compared to its average volume of 12,828,560. The company has a market cap of $113.56 billion, a PE ratio of 15.62, a P/E/G ratio of 0.16 and a beta of 0.24. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The stock’s 50 day moving average price is $57.19 and its two-hundred day moving average price is $57.22.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period in the previous year, the firm posted $1.80 EPS. The firm’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.5%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.

Institutional Trading of Bristol Myers Squibb

Large investors have recently bought and sold shares of the business. Norges Bank acquired a new position in Bristol Myers Squibb during the 4th quarter valued at about $1,947,272,000. AQR Capital Management LLC lifted its holdings in shares of Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after purchasing an additional 16,332,924 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Bristol Myers Squibb by 47.0% during the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock worth $1,321,308,000 after buying an additional 7,837,485 shares in the last quarter. Geode Capital Management LLC grew its holdings in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after buying an additional 6,084,046 shares in the last quarter. Finally, Man Group plc raised its position in Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after buying an additional 5,503,391 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.05% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Royal Bank Of Canada started coverage on Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price target for the company. Guggenheim restated a “buy” rating and set a $72.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Cantor Fitzgerald boosted their target price on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, April 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $61.31.

Read Our Latest Analysis on Bristol Myers Squibb

About Representative Kelly

Mike Kelly (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 16th Congressional District. He assumed office on January 3, 2019. His current term ends on January 3, 2027.

Kelly (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 16th Congressional District. He declared candidacy for the 2026 election.

Bristol Myers Squibb Company Profile

(Get Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.